Amphastar Pharmaceuticals (NASDAQ:AMPH) Downgraded to “C” at TheStreet

TheStreet downgraded shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) from a b- rating to a c rating in a report published on Thursday morning, TheStreetRatingsTable reports.

Other analysts also recently issued research reports about the stock. Zacks Investment Research downgraded shares of Amphastar Pharmaceuticals from a buy rating to a hold rating in a report on Thursday, October 24th. ValuEngine downgraded shares of Amphastar Pharmaceuticals from a buy rating to a hold rating in a report on Friday, September 20th. Finally, BidaskClub downgraded shares of Amphastar Pharmaceuticals from a hold rating to a sell rating in a report on Tuesday, October 29th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating to the stock. The stock presently has an average rating of Hold and a consensus target price of $24.44.

AMPH stock traded down $0.71 during midday trading on Thursday, hitting $18.41. The company’s stock had a trading volume of 600,700 shares, compared to its average volume of 195,968. The company has a debt-to-equity ratio of 0.13, a current ratio of 2.81 and a quick ratio of 1.83. The stock has a market capitalization of $918.08 million, a P/E ratio of 87.67 and a beta of 1.17. Amphastar Pharmaceuticals has a twelve month low of $16.92 and a twelve month high of $25.43. The company’s fifty day moving average price is $19.87 and its 200 day moving average price is $20.65.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings data on Thursday, November 7th. The company reported $0.10 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.08 by $0.02. The firm had revenue of $80.14 million during the quarter, compared to the consensus estimate of $78.53 million. Amphastar Pharmaceuticals had a net margin of 16.33% and a return on equity of 5.52%. The business’s revenue for the quarter was up 6.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.12 EPS. Equities analysts expect that Amphastar Pharmaceuticals will post 0.17 EPS for the current fiscal year.

In other news, SVP Yakob Liawatidewi sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $20.73, for a total value of $103,650.00. Following the completion of the transaction, the senior vice president now directly owns 47,188 shares in the company, valued at approximately $978,207.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Richard K. Prins sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $20.78, for a total transaction of $207,800.00. Following the completion of the transaction, the director now owns 49,309 shares of the company’s stock, valued at $1,024,641.02. The disclosure for this sale can be found here. Insiders sold a total of 354,479 shares of company stock valued at $7,415,153 over the last 90 days. Corporate insiders own 30.80% of the company’s stock.

Large investors have recently modified their holdings of the company. Acadian Asset Management LLC acquired a new position in shares of Amphastar Pharmaceuticals in the 2nd quarter valued at approximately $88,000. Bank of Montreal Can raised its position in shares of Amphastar Pharmaceuticals by 130.7% in the 2nd quarter. Bank of Montreal Can now owns 4,923 shares of the company’s stock valued at $104,000 after buying an additional 2,789 shares in the last quarter. Magnus Financial Group LLC acquired a new position in shares of Amphastar Pharmaceuticals in the 2nd quarter valued at approximately $204,000. JPMorgan Chase & Co. raised its position in shares of Amphastar Pharmaceuticals by 15.4% in the 2nd quarter. JPMorgan Chase & Co. now owns 9,856 shares of the company’s stock valued at $205,000 after buying an additional 1,314 shares in the last quarter. Finally, A.R.T. Advisors LLC acquired a new position in shares of Amphastar Pharmaceuticals in the 2nd quarter valued at approximately $208,000. Institutional investors own 47.21% of the company’s stock.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients products.

Featured Article: Accumulation/Distribution

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.